Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women
MN Sack, DJ Rader, RO Cannon - The Lancet, 1994 - Elsevier
MN Sack, DJ Rader, RO Cannon
The Lancet, 1994•ElsevierOxidative modification of low-density lipoprotein (LDL) may be atherogenic. We studied the
time of onset of LDL oxidation (lag) in 18 postmenopausal women before and after intra-
arterial infusion of 17 β-oestradiol, after 3 weeks' patch administration in 12 of these women,
and 1 month after discontinuation in 10. The lag increased from baseline after acute infusion
(from 134 [SD 41] to 167 [36] min, p= 0· 01) and after the patch (132 [31] to 178 [45] min, p=
0· 009). After discontinuation of oestradiol, the lag returned to baseline. This study shows an …
time of onset of LDL oxidation (lag) in 18 postmenopausal women before and after intra-
arterial infusion of 17 β-oestradiol, after 3 weeks' patch administration in 12 of these women,
and 1 month after discontinuation in 10. The lag increased from baseline after acute infusion
(from 134 [SD 41] to 167 [36] min, p= 0· 01) and after the patch (132 [31] to 178 [45] min, p=
0· 009). After discontinuation of oestradiol, the lag returned to baseline. This study shows an …
Abstract
Oxidative modification of low-density lipoprotein (LDL) may be atherogenic. We studied the time of onset of LDL oxidation (lag) in 18 postmenopausal women before and after intra-arterial infusion of 17 β-oestradiol, after 3 weeks' patch administration in 12 of these women, and 1 month after discontinuation in 10. The lag increased from baseline after acute infusion (from 134 [SD 41] to 167 [36] min, p=0·01) and after the patch (132 [31] to 178 [45] min, p=0·009). After discontinuation of oestradiol, the lag returned to baseline. This study shows an antioxidant effect of physiological levels of 17 β-oestradiol, which may contribute to an anti-atherogenic action.
Elsevier